Alvogen’s Chairman & CEO Robert Wessman is the new Chairman of the Board at the publicly listed Lotus Pharmaceuticals in Taiwan, succeeding Andrew Lin. Lotus Pharmaceuticals, which is majority-owned by Alvogen, has been under the leadership and guidance of Lin since 2016. Lin will continue to support Lotus as a director of the board.
Wessman’s current role at Alvogen will remain unchanged as he pursues continued growth with Lotus, which is poised to become a leading developer and supplier of oncology products globally.
Commenting on his new role, Wessman said:
Lotus is a pharmaceutical company headquartered in Taiwan, primarily focusing on addressing the fast-growing oncology market and exclusive marketing of biosimilars in the APAC region. The company boasts a best in class R&D and manufacturing platform in both Taiwan and Korea. Its partnership with Alvogen, along with alliances with other top-tier pharma companies, allows Lotus to reach worldwide markets.